The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Factors to consider when choosing between ‘watch and wait’ versus early intervention in SMM
Irene Ghobrial, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses factors that are important to consider when deciding whether to treat individuals with smoldering multiple myeloma (SMM). Dr Ghobrial comments on the importance of improving risk stratification tools, and further emphasizes the benefit of using immunotherapeutic agents as early as possible, as this may reduce the toxicities associated with these therapies. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
